JP2018513832A5 - - Google Patents

Download PDF

Info

Publication number
JP2018513832A5
JP2018513832A5 JP2017541855A JP2017541855A JP2018513832A5 JP 2018513832 A5 JP2018513832 A5 JP 2018513832A5 JP 2017541855 A JP2017541855 A JP 2017541855A JP 2017541855 A JP2017541855 A JP 2017541855A JP 2018513832 A5 JP2018513832 A5 JP 2018513832A5
Authority
JP
Japan
Prior art keywords
optionally substituted
compound according
hydrogen
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017541855A
Other languages
English (en)
Japanese (ja)
Other versions
JP6769000B2 (ja
JP2018513832A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2016/077519 external-priority patent/WO2016155593A1/zh
Publication of JP2018513832A publication Critical patent/JP2018513832A/ja
Publication of JP2018513832A5 publication Critical patent/JP2018513832A5/ja
Application granted granted Critical
Publication of JP6769000B2 publication Critical patent/JP6769000B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017541855A 2015-04-03 2016-03-28 4’−チオヌクレオシドの新規な化合物、並びにその調製方法、その医薬組成物及びその用途 Expired - Fee Related JP6769000B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510157772 2015-04-03
CN201510157772.0 2015-04-03
PCT/CN2016/077519 WO2016155593A1 (zh) 2015-04-03 2016-03-28 4'-硫代核苷的新型化合物及其制备方法、药物组合物和应用

Publications (3)

Publication Number Publication Date
JP2018513832A JP2018513832A (ja) 2018-05-31
JP2018513832A5 true JP2018513832A5 (enExample) 2019-03-28
JP6769000B2 JP6769000B2 (ja) 2020-10-14

Family

ID=57004251

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017541855A Expired - Fee Related JP6769000B2 (ja) 2015-04-03 2016-03-28 4’−チオヌクレオシドの新規な化合物、並びにその調製方法、その医薬組成物及びその用途

Country Status (8)

Country Link
US (2) US10662214B2 (enExample)
EP (1) EP3279207B1 (enExample)
JP (1) JP6769000B2 (enExample)
CN (2) CN106661077B (enExample)
AU (1) AU2016240117C1 (enExample)
CA (1) CA2975990A1 (enExample)
EA (1) EA034375B1 (enExample)
WO (1) WO2016155593A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170082650A (ko) 2012-03-28 2017-07-14 후지필름 가부시키가이샤 1-(2-디옥시-2-플루오로-4-티오-β-D-아라비노푸라노실)시토신의 염
KR101770248B1 (ko) 2012-08-13 2017-08-22 후지필름 가부시키가이샤 1-(2-데옥시-2-플루오로-4-티오-β-D-아라비노푸라노실)시토신의 합성 중간체, 티오뉴클레오시드의 합성 중간체, 및 그들의 제조법
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
WO2016155593A1 (zh) * 2015-04-03 2016-10-06 四川科伦药物研究院有限公司 4'-硫代核苷的新型化合物及其制备方法、药物组合物和应用
RU2752172C2 (ru) 2016-08-31 2021-07-23 Фуджифилм Корпорэйшн Противоопухолевый агент, усилитель противоопухолевого действия и противоопухолевый набор
CA3041420A1 (en) * 2016-12-22 2018-06-28 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Solid form of 4'-thio-2'-fluoronucleoside phosphamide compound and preparation method therefor and use thereof
WO2019001292A1 (zh) * 2017-06-29 2019-01-03 四川科伦博泰生物医药股份有限公司 4'-硫代核苷的新型化合物的制备方法和此制备方法中的中间体
CN110831604B (zh) * 2017-09-01 2023-05-02 四川科伦博泰生物医药股份有限公司 用于肿瘤治疗或预防的药物组合物、方法及其用途
AU2018404329B2 (en) 2018-01-29 2021-09-09 Fujifilm Corporation Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
EP4209498A1 (en) * 2018-04-19 2023-07-12 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
WO2020108343A1 (zh) * 2018-11-28 2020-06-04 四川科伦博泰生物医药股份有限公司 以4'-硫代核苷类化合物为活性成分的口服药物组合物、其制备方法及其用途
CN114341149A (zh) * 2019-07-30 2022-04-12 匹诺生物股份有限公司 用于治疗癌症的二核苷酸化合物及其医学用途
US12208112B2 (en) 2020-04-23 2025-01-28 Southern Research Institute Composition for treating blood cancer using 4′-thio-5-Aza-2′-deoxycytidine and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128458A (en) 1990-04-20 1992-07-07 Southern Research Institute 2',3'-dideoxy-4'-thioribonucleosides as antiviral agents
DK0841344T3 (da) * 1996-04-09 2002-12-23 Yamasa Corp 1-(2-Desoxy-2-fluor-4-thio-Beta-D-arabinofuranosyl)cytosiner
JPH1087687A (ja) * 1996-04-09 1998-04-07 Yamasa Shoyu Co Ltd 5−置換−1−(2−デオキシ−2−フルオロ−4−チオ−β−D−アラビノフラノシル)ウラシル
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
AU2004274021B2 (en) 2003-09-18 2009-08-13 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
US7888330B2 (en) 2005-11-09 2011-02-15 Wayne State University Phosphoramidate derivatives of FAU
GB201016855D0 (en) * 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
CN103987712B (zh) * 2011-07-19 2016-05-04 河南美泰宝生物制药有限公司 2’,3’-二脱氧-2’-α-氟-2’-β-C-甲基核苷和其前药
WO2014124430A1 (en) * 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2014197578A1 (en) * 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
TWI678373B (zh) * 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
WO2016155593A1 (zh) * 2015-04-03 2016-10-06 四川科伦药物研究院有限公司 4'-硫代核苷的新型化合物及其制备方法、药物组合物和应用

Similar Documents

Publication Publication Date Title
JP2018513832A5 (enExample)
ES2925564T3 (es) Derivados de azetidina tal como moduladores de receptores de quimiocinas y usos de los mismos
JP5271913B2 (ja) 化合物
ES2804101T3 (es) Compuestos de 4-amino-imidazoquinolina
KR101612642B1 (ko) 테노포비어 알라펜아미드 헤미푸마레이트
ES2654161T3 (es) Compuestos químicos
JP2020515610A5 (enExample)
RU2007124329A (ru) ПРОИЗВОДНЫЕ 5-ГИДРОКСИБЕНЗОТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНОРЕЦЕПТОРОВ
JP2013010792A5 (enExample)
RU2005107314A (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью
KR101986272B1 (ko) 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도
JP2013056886A5 (enExample)
KR20150046315A (ko) 테노포비르 전구약물 및 그의 약학적 용도
WO2012118978A1 (en) Methods for treating oncovirus positive cancers
JP2015508092A5 (enExample)
JP2017534657A (ja) 新型シチジン誘導体およびその適用
JP2020516616A5 (enExample)
CN105518012B (zh) 一种取代的氨基酸硫酯类化合物、其组合物及应用
JP6872179B2 (ja) テノホビルプロドラッグの新規な多結晶形並びにその製造方法及び用途
JP2015502371A5 (enExample)
TWI638825B (zh) 抑制癌症及病毒之化合物
JP6184866B2 (ja) 新規抗がん剤
CA2552855A1 (en) Azabicyclooctan-3-one derivatives and use thereof
RU2008112181A (ru) Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3
JP2013525290A5 (enExample)